Source: Annual Congress 2004 - Advancements in pathobiology of respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. G. Franciosi, C. P. Page, B. R. Celli, M. Cazzola, M. J. Walker, M. Danhof, K. F. Rabe, O. E. Della Pasqua (Leiden, The Netherlands; London, Greenford, United Kingdom; Boston, United States Of America; Naples, Italy; Vancouver, Canada). Which markers other than FEV₁ reflect disease progression in COPD?. Eur Respir J 2004; 24: Suppl. 48, 406

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 The relationship between bronchial inflammation and markers of disease progression in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Does rapid decline predict poor prognosis? Source: Annual Congress 2007 - Rapid decline in lung function and its consequences Year: 2007 FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline? Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Lung function reversibility as a predictor of disease progression in COPD Source: International Congress 2017 – Markers of COPD progression Year: 2017 Are COPD exacerbations associated with the severity of the disease? Source: Eur Respir J 2005; 26: Suppl. 49, 300s Year: 2005 Does the 2011 GOLD staging of COPD reflect phenotype and severity of the disease as assessed by CT? Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Hyaluronic acid as a novel systemic biomarker to predict progression and severity in chronic obstructive pulmonary disease Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021 Lung function indices versus symptoms for monitoring the course of the disease in patients with COPD Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Predictors for the rapid decline of FEV1 in chronic obstructive lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 255s Year: 2002 Evidence for the onset of COPD in childhood, and the role of genetics Source: Annual Congress 2005 - Does COPD begin in childhood? Reviewing the evidence Year: 2005 Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Cough rate may predict disease severity in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 536s Year: 2004 Study assoicção between severity stages of chronic obstructive pulmonary disease and fasting glucose in patients with this disease Source: Annual Congress 2013 –COPD and tobacco management Year: 2013 Markers of early disease and prognosis in COPD Source: Annual Congress 2009 - Epidemiology of COPD Year: 2009 Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013